Pathological findings in central nervous system demyelination associated with infliximab
Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from mu...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2020-08, Vol.26 (9), p.1124-1129 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1129 |
|---|---|
| container_issue | 9 |
| container_start_page | 1124 |
| container_title | Multiple sclerosis |
| container_volume | 26 |
| creator | Kalinowska-Lyszczarz, Alicja Fereidan-Esfahani, Mahboobeh Guo, Yong Lucchinetti, Claudia F Tobin, W Oliver |
| description | Background:
Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders.
Objective:
To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS).
Methods:
We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described.
Results and conclusion:
Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS. |
| doi_str_mv | 10.1177/1352458519894710 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7297659</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458519894710</sage_id><sourcerecordid>2327941108</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-98eedf45894e67b1959d52c6ed95c15049fb9e0379af63fa8118b23e71746fb13</originalsourceid><addsrcrecordid>eNp1Uc9r2zAYFaOjSbPedxqGXnbxps-SLOtSKKXrBoX20MFuQrY_JQq2lFpOu_z3VUiWtYWeJPR-6D0eIZ-BfgOQ8jswUXBRCVCV4hLoBzIFLmVOlaRH6Z7gfItPyEmMS0qplEwckwmDiosSyin5c2fGRejC3DWmy6zzrfPzmDmfNejHIb15HB7DOmZxE0fssxb7DXbOm9EFn5kYQ-PMiG325MZF0tnO_XW9qT-Rj9Z0EU_354z8_nF1f_kzv7m9_nV5cZM3vCzGXFWIrU0ZFcdS1qCEakXRlNgq0YCgXNlaIWVSGVsyayqAqi4YSpC8tDWwGTnf-a7WdY_tPrVeDSnEsNHBOP0a8W6h5-FRy0LJUqhk8HVvMISHNcZR9y422HXGY-qtC1ZIxQFolahnb6jLsB58qqcLzqgSFOjWkO5YzRBiHNAewgDV29n029mS5MvLEgfBv50SId8Ropnj_1_fNXwGytKhJg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2430950109</pqid></control><display><type>article</type><title>Pathological findings in central nervous system demyelination associated with infliximab</title><source>SAGE Complete</source><creator>Kalinowska-Lyszczarz, Alicja ; Fereidan-Esfahani, Mahboobeh ; Guo, Yong ; Lucchinetti, Claudia F ; Tobin, W Oliver</creator><creatorcontrib>Kalinowska-Lyszczarz, Alicja ; Fereidan-Esfahani, Mahboobeh ; Guo, Yong ; Lucchinetti, Claudia F ; Tobin, W Oliver</creatorcontrib><description>Background:
Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders.
Objective:
To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS).
Methods:
We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described.
Results and conclusion:
Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458519894710</identifier><identifier>PMID: 31845616</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Central nervous system ; Demyelination ; Immunotherapy ; Inflammation ; Infliximab ; Monoclonal antibodies ; Multiple sclerosis ; Nervous system ; Rheumatoid arthritis ; TNF inhibitors ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α</subject><ispartof>Multiple sclerosis, 2020-08, Vol.26 (9), p.1124-1129</ispartof><rights>The Author(s), 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-98eedf45894e67b1959d52c6ed95c15049fb9e0379af63fa8118b23e71746fb13</citedby><cites>FETCH-LOGICAL-c462t-98eedf45894e67b1959d52c6ed95c15049fb9e0379af63fa8118b23e71746fb13</cites><orcidid>0000-0002-8141-2394</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458519894710$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458519894710$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>230,314,777,781,882,21800,27905,27906,43602,43603</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31845616$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kalinowska-Lyszczarz, Alicja</creatorcontrib><creatorcontrib>Fereidan-Esfahani, Mahboobeh</creatorcontrib><creatorcontrib>Guo, Yong</creatorcontrib><creatorcontrib>Lucchinetti, Claudia F</creatorcontrib><creatorcontrib>Tobin, W Oliver</creatorcontrib><title>Pathological findings in central nervous system demyelination associated with infliximab</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Background:
Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders.
Objective:
To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS).
Methods:
We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described.
Results and conclusion:
Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.</description><subject>Central nervous system</subject><subject>Demyelination</subject><subject>Immunotherapy</subject><subject>Inflammation</subject><subject>Infliximab</subject><subject>Monoclonal antibodies</subject><subject>Multiple sclerosis</subject><subject>Nervous system</subject><subject>Rheumatoid arthritis</subject><subject>TNF inhibitors</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1Uc9r2zAYFaOjSbPedxqGXnbxps-SLOtSKKXrBoX20MFuQrY_JQq2lFpOu_z3VUiWtYWeJPR-6D0eIZ-BfgOQ8jswUXBRCVCV4hLoBzIFLmVOlaRH6Z7gfItPyEmMS0qplEwckwmDiosSyin5c2fGRejC3DWmy6zzrfPzmDmfNejHIb15HB7DOmZxE0fssxb7DXbOm9EFn5kYQ-PMiG325MZF0tnO_XW9qT-Rj9Z0EU_354z8_nF1f_kzv7m9_nV5cZM3vCzGXFWIrU0ZFcdS1qCEakXRlNgq0YCgXNlaIWVSGVsyayqAqi4YSpC8tDWwGTnf-a7WdY_tPrVeDSnEsNHBOP0a8W6h5-FRy0LJUqhk8HVvMISHNcZR9y422HXGY-qtC1ZIxQFolahnb6jLsB58qqcLzqgSFOjWkO5YzRBiHNAewgDV29n029mS5MvLEgfBv50SId8Ropnj_1_fNXwGytKhJg</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Kalinowska-Lyszczarz, Alicja</creator><creator>Fereidan-Esfahani, Mahboobeh</creator><creator>Guo, Yong</creator><creator>Lucchinetti, Claudia F</creator><creator>Tobin, W Oliver</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8141-2394</orcidid></search><sort><creationdate>20200801</creationdate><title>Pathological findings in central nervous system demyelination associated with infliximab</title><author>Kalinowska-Lyszczarz, Alicja ; Fereidan-Esfahani, Mahboobeh ; Guo, Yong ; Lucchinetti, Claudia F ; Tobin, W Oliver</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-98eedf45894e67b1959d52c6ed95c15049fb9e0379af63fa8118b23e71746fb13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Central nervous system</topic><topic>Demyelination</topic><topic>Immunotherapy</topic><topic>Inflammation</topic><topic>Infliximab</topic><topic>Monoclonal antibodies</topic><topic>Multiple sclerosis</topic><topic>Nervous system</topic><topic>Rheumatoid arthritis</topic><topic>TNF inhibitors</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kalinowska-Lyszczarz, Alicja</creatorcontrib><creatorcontrib>Fereidan-Esfahani, Mahboobeh</creatorcontrib><creatorcontrib>Guo, Yong</creatorcontrib><creatorcontrib>Lucchinetti, Claudia F</creatorcontrib><creatorcontrib>Tobin, W Oliver</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kalinowska-Lyszczarz, Alicja</au><au>Fereidan-Esfahani, Mahboobeh</au><au>Guo, Yong</au><au>Lucchinetti, Claudia F</au><au>Tobin, W Oliver</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pathological findings in central nervous system demyelination associated with infliximab</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>26</volume><issue>9</issue><spage>1124</spage><epage>1129</epage><pages>1124-1129</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><abstract>Background:
Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders.
Objective:
To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS).
Methods:
We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described.
Results and conclusion:
Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>31845616</pmid><doi>10.1177/1352458519894710</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-8141-2394</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2020-08, Vol.26 (9), p.1124-1129 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7297659 |
| source | SAGE Complete |
| subjects | Central nervous system Demyelination Immunotherapy Inflammation Infliximab Monoclonal antibodies Multiple sclerosis Nervous system Rheumatoid arthritis TNF inhibitors Tumor necrosis factor-TNF Tumor necrosis factor-α |
| title | Pathological findings in central nervous system demyelination associated with infliximab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T20%3A01%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pathological%20findings%20in%20central%20nervous%20system%20demyelination%20associated%20with%20infliximab&rft.jtitle=Multiple%20sclerosis&rft.au=Kalinowska-Lyszczarz,%20Alicja&rft.date=2020-08-01&rft.volume=26&rft.issue=9&rft.spage=1124&rft.epage=1129&rft.pages=1124-1129&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/1352458519894710&rft_dat=%3Cproquest_pubme%3E2327941108%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2430950109&rft_id=info:pmid/31845616&rft_sage_id=10.1177_1352458519894710&rfr_iscdi=true |